Celera Genomics signs Vita Genomics to database subscription deal
Under the terms of the agreement, Vita Genomic's researchers will gain access to the Celera Discovery System to use Celera's integrated database products, bioinformatics systems and other discovery tools to conduct genomics research. Financial terms of the agreement were not disclosed.
"This agreement with Vita Genomics is important as it is the first company in Taiwan to access Celera's genomic databases," said Craig Venter, Celera's President and CSO.
"Through the Celera Discovery System, researchers worldwide have immediate desktop access to some of the most advanced tools and systems with which to analyze and interpret the Celera generated genomic and biological data as well as publicly available data. The ability to integrate these massive amounts of data through one system should allow scientists to find particular disease genes, better understand genetic variation and its role in disease, as well as gain insight into the function of proteins within the body."
The Celera Discovery System is an integrated, Web-based discovery system designed to allow subscribers to use Celera generated databases, additional non-proprietary genome and biological datasets, computational tools and super-computing power to advance the discovery programs of researchers worldwide.
"We are very pleased to work with Celera Genomics, a premier genomics and biological information company," said Ellson Chen, President and CEO of Vita Genomics, and formerly a principal scientist at Celera. "Using Celera's datasets, we intend to uncover targets for human diseases prevalent in the Taiwanese population as a basis for understanding the causes of disease in the Asia Pacific region and to develop and commercialize products for diagnosing, treating and preventing these diseases."